Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 80

1.

FKBP51 affects cancer cell response to chemotherapy by negatively regulating Akt.

Pei H, Li L, Fridley BL, Jenkins GD, Kalari KR, Lingle W, Petersen G, Lou Z, Wang L.

Cancer Cell. 2009 Sep 8;16(3):259-66. doi: 10.1016/j.ccr.2009.07.016.

2.

USP49 negatively regulates tumorigenesis and chemoresistance through FKBP51-AKT signaling.

Luo K, Li Y, Yin Y, Li L, Wu C, Chen Y, Nowsheen S, Hu Q, Zhang L, Lou Z, Yuan J.

EMBO J. 2017 May 15;36(10):1434-1446. doi: 10.15252/embj.201695669. Epub 2017 Mar 31.

PMID:
28363942
3.

A molecular link between AKT regulation and chemotherapeutic response.

Dibble CC, Manning BD.

Cancer Cell. 2009 Sep 8;16(3):178-80. doi: 10.1016/j.ccr.2009.08.011.

4.

FKBP5 as a selection biomarker for gemcitabine and Akt inhibitors in treatment of pancreatic cancer.

Hou J, Wang L.

PLoS One. 2012;7(5):e36252. doi: 10.1371/journal.pone.0036252. Epub 2012 May 9.

5.

InterAKTions with FKBPs--mutational and pharmacological exploration.

Fabian AK, März A, Neimanis S, Biondi RM, Kozany C, Hausch F.

PLoS One. 2013;8(2):e57508. doi: 10.1371/journal.pone.0057508. Epub 2013 Feb 28.

6.

FKBP51 regulation of AKT/protein kinase B phosphorylation.

Wang L.

Curr Opin Pharmacol. 2011 Aug;11(4):360-4. doi: 10.1016/j.coph.2011.03.008. Epub 2011 Apr 15. Review.

7.

Assembly of the FKBP51-PHLPP2-AKT signaling complex in cerebral ischemia/reperfusion injury in rats.

Wei XE, Zhang FY, Wang K, Zhang QX, Rong LQ.

Brain Res. 2014 May 30;1566:60-8. doi: 10.1016/j.brainres.2014.04.009. Epub 2014 Apr 16.

PMID:
24746496
8.

PHLPP negatively regulates cell motility through inhibition of Akt activity and integrin expression in pancreatic cancer cells.

Smith AJ, Wen YA, Stevens PD, Liu J, Wang C, Gao T.

Oncotarget. 2016 Feb 16;7(7):7801-15. doi: 10.18632/oncotarget.6848.

9.

Emerging role of FKBP51 in AKT kinase/protein kinase B signaling.

Pei H, Lou Z, Wang L.

Cell Cycle. 2010 Jan 1;9(1):6-7. Epub 2010 Jan 9. No abstract available.

PMID:
20016266
10.

Regulation of Serine-Threonine Kinase Akt Activation by NAD+-Dependent Deacetylase SIRT7.

Yu J, Qin B, Wu F, Qin S, Nowsheen S, Shan S, Zayas J, Pei H, Lou Z, Wang L.

Cell Rep. 2017 Jan 31;18(5):1229-1240. doi: 10.1016/j.celrep.2017.01.009.

11.
12.

The phosphatase PHLPP1 regulates Akt2, promotes pancreatic cancer cell death, and inhibits tumor formation.

Nitsche C, Edderkaoui M, Moore RM, Eibl G, Kasahara N, Treger J, Grippo PJ, Mayerle J, Lerch MM, Gukovskaya AS.

Gastroenterology. 2012 Feb;142(2):377-87.e1-5. doi: 10.1053/j.gastro.2011.10.026. Epub 2011 Oct 29.

13.

The emerging role of large immunophilin FK506 binding protein 51 in cancer.

Romano S, Sorrentino A, Di Pace AL, Nappo G, Mercogliano C, Romano MF.

Curr Med Chem. 2011;18(35):5424-9. Review.

14.

The deubiquitination enzyme USP46 functions as a tumor suppressor by controlling PHLPP-dependent attenuation of Akt signaling in colon cancer.

Li X, Stevens PD, Yang H, Gulhati P, Wang W, Evers BM, Gao T.

Oncogene. 2013 Jan 24;32(4):471-8. doi: 10.1038/onc.2012.66. Epub 2012 Mar 5.

15.

The phosphatase PHLPP controls the cellular levels of protein kinase C.

Gao T, Brognard J, Newton AC.

J Biol Chem. 2008 Mar 7;283(10):6300-11. Epub 2007 Dec 27.

16.

PHLPP-1 negatively regulates Akt activity and survival in the heart.

Miyamoto S, Purcell NH, Smith JM, Gao T, Whittaker R, Huang K, Castillo R, Glembotski CC, Sussman MA, Newton AC, Brown JH.

Circ Res. 2010 Aug 20;107(4):476-84. doi: 10.1161/CIRCRESAHA.109.215020. Epub 2010 Jun 24.

17.

Photoreceptor Neuroprotection: Regulation of Akt Activation Through Serine/Threonine Phosphatases, PHLPP and PHLPPL.

Rajala RV, Kanan Y, Anderson RE.

Adv Exp Med Biol. 2016;854:419-24. doi: 10.1007/978-3-319-17121-0_55.

PMID:
26427440
18.

Suppression of survival signalling pathways by the phosphatase PHLPP.

O'Neill AK, Niederst MJ, Newton AC.

FEBS J. 2013 Jan;280(2):572-83. doi: 10.1111/j.1742-4658.2012.08537.x. Epub 2012 Mar 16.

19.

FKBP51 and Cyp40 are positive regulators of androgen-dependent prostate cancer cell growth and the targets of FK506 and cyclosporin A.

Periyasamy S, Hinds T Jr, Shemshedini L, Shou W, Sanchez ER.

Oncogene. 2010 Mar 18;29(11):1691-701. doi: 10.1038/onc.2009.458. Epub 2009 Dec 21.

20.

PHLPP-mediated dephosphorylation of S6K1 inhibits protein translation and cell growth.

Liu J, Stevens PD, Li X, Schmidt MD, Gao T.

Mol Cell Biol. 2011 Dec;31(24):4917-27. doi: 10.1128/MCB.05799-11. Epub 2011 Oct 10.

Supplemental Content

Support Center